Discovery Laboratories has initiated its controversial Phase III trialof its humanized lung surfactant Surfaxin (lucinactant) in the prevention and treatment of idiopathic respiratory distress syndrome in premature infants. The study design had been criticized by US consumer organization Public Citizen's Health Research Group for including a placebo arm (Marketletter March 5). Around 1,500 patients will be included in the trial, which will take place in North and South America and Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze